ArticleJournal of thrombosis and thrombolysis2025
LncRNA CASC2 mediates the lower extremity deep vein thrombosis via sponging miR-152-3p.
Article in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Circulating MicroRNAs as Biomarkers and Therapeutic Targets in Venous Thromboembolism: A Systematic Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower extremity deep vein thrombosis (DVT) is a prevalent form of peripheral vascular disease, notable for its high incidence rate. We investigated the potential mechanisms through which the long non-coding RNA (lncRNA) CASC2/miR-152-3p axis regulates the DVT.
methods150 patients diagnosed with DVT and 150 controls were included. CASC2 and miR-152-3p levels were quantified using RT-qPCR. HUVECs viability was assessed via the CCK-8 assay, while cell migration was evaluated using Transwell chamber assays. Flow cytometry was employed to determine cell apoptosis. Tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), ICAM, and VCAM concentrations were measured through ELISA. The interaction between lncRNA CASC2 and miR-152-3p was validated using a dual-luciferase reporter assay. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted for function and pathway enrichment.
resultsLncRNA CASC2 was significantly downregulated in DVT patients. LncRNA CASC2 was independently associated with the occurrence of DVT and demonstrated a relatively high diagnostic value. Overexpression of lncRNA CASC2 significantly enhanced HUVEC's proliferation and migration, while reducing apoptosis and the concentrations of TNF-α, IL-1β, IL-6, ICAM-1, and VCAM-1. Conversely, the knockdown of lncRNA CASC2 resulted in opposite effects. LncRNA CASC2 directly targeted and negatively regulated miR-152-3p. Additionally, miR-152-3p counteracted the effects of lncRNA CASC2 on cell function. GO and KEGG analyses revealed that the target genes of miR-152-3p were mainly involved in the TGF-β and PI3K-Akt signaling pathways.
conclusionThe lncRNA CASC2/miR-152-3p axis played a critical role in mediating the formation of DVT.
Indexed as
Identifiers
40593456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.